Objective: To investigate the migration and invasion effects and its mechanism of bortezomib on prostate cancer cell in vitro. Methods: Selected LNCAP logarithmic growth of prostate cancer cell lines, given with different levels of bortezomib treatment. After 24h, the migration and invasion of prostate cancer were detected, and we collected cells for expression of inflammatory cytokines experiments and Western blot analysis. Results: The cell migration index and invasion index of the LNCAP + bortezomib (10nmol / L) group and LNCAP + bortezomib (20nmol / L) group were significantly lower than for individual LNCAP group, and the IL-12 and TNF-α expression levels were also significantly lower than single LNCAP group, compared to the differences were statistically significant (P <0.05). When  given the different levels of bortezomib treatment in the LNCAP cells after 24h, The total protein FAK changes showed no significant data (P> 0.05). Conclusion: Bortezomib can effectively inhibit the migration and invasion of prostate cancer cells, and it may  inhibite the expression of IL-12 and TNF-αbut it had no effect on the expression of total FAK protein.